DONGWHA PHARM.CO.,LTD
Financials
Valuation Metrics
DONGWHA PHARM.CO.,LTD's Market Cap is ₩1408B. At end of 2025 it was ₩1746B. Ranked #1060 of 2,421 in KR market (top 44%), #516 of 781 on KOSPI (top 66%), #121 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 140.77B KRW | KR#1,060/2,421 Sec#121/231 |
| Revenue | 513.24B KRW | KR#614/2,421 Sec#31/231 |
| Net Income | 14.62B KRW | KR#827/2,421 Sec#55/231 |
| Total Assets | 653.67B KRW | KR#644/2,421 Sec#35/231 |
| Net Assets | 415.47B KRW | KR#583/2,421 Sec#35/231 |
| Employees | 824 | KR#304/2,421 Sec#25/231 |
| Value | ||
| P/E | 9.63x | KR#775/2,421 Sec#39/231 |
| P/B | 0.34x | KR#408/2,421 Sec#14/231 |
| P/S | 0.27x | KR#538/2,421 Sec#11/231 |
| EV/EBITDA | 11.95x | KR#717/2,421 Sec#39/231 |
| FCF Yield | -26.62% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 3.52% | KR#1,282/2,421 Sec#88/231 |
| ROA | 2.24% | KR#1,175/2,421 Sec#87/231 |
| Op. Margin | 3.68% | KR#1,139/2,421 Sec#82/231 |
| Revenue Growth | 6.59% | KR#1,100/2,421 Sec#108/231 |
| Financial Health | ||
| Debt Ratio | 57.34% | KR#1,063/2,421 Sec#123/231 |
| Total Debt | 107.12B KRW | KR#702/2,421 Sec#43/231 |
| FCF | -37.48B KRW | KR#2,027/2,421 Sec#199/231 |
| Cash | 22.05B KRW | KR#1,193/2,421 Sec#82/231 |
| Current Ratio | 1.22x | KR#1,481/2,421 Sec#153/231 |
| Net Debt/EBITDA | 4.50x | KR#999/2,421 Sec#73/231 |
| Dividend | ||
| Div. Yield | 1.29% | KR#1,048/2,421 Sec#57/231 |
| Div. Growth | -63.89% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -21.25% | KR#1,292/2,421 Sec#91/231 |
| 1M Return | -0.59% | KR#1,302/2,421 Sec#98/231 |
| From 52W High | -33.33% | KR#651/2,421 Sec#40/231 |
| 1Y MDD | -31.78% | KR#306/2,421 Sec#22/231 |
| Trading | ||
| Volume | 48,055 shares | KR#1,149/2,421 Sec#113/231 |
| Trading Value | 243.1M KRW | KR#1,199/2,421 Sec#121/231 |
| Foreign Own. | 3.22% | KR#1,224/2,421 Sec#112/231 |
| Per Share | ||
| EPS | 524 KRW | KR#977/2,421 Sec#70/231 |
| BPS | 14,874 KRW | KR#706/2,421 Sec#46/231 |
Company Info
Established in 1897 and listed on the Stock Market in 1976, this pharmaceutical company acquired medical device manufacturer Medyssey in 2020 and Vietnamese pharmaceutical distribution chain TS Care in 2023. It specializes in manufacturing and selling pharmaceuticals, active pharmaceutical ingredients, quasi-drugs, and medical devices, also producing health functional foods. The company targets sustainable growth by addressing an aging society, improving economic standards, and developing biotech new drugs for intractable diseases. Dong Wha Pharmaceutical is headquartered in Jung-gu, Seoul Metropolitan City.